Connect Biopharma Holdings Ltd
NASDAQ:CNTB
Intrinsic Value
Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. [ Read More ]
The intrinsic value of one
CNTB
stock under the Base Case scenario is
2.11
USD.
Compared to the current market price of 1.54 USD,
Connect Biopharma Holdings Ltd
is
Undervalued by 27%.
Connect Biopharma Holdings Ltd's market capitalization is 84.8m USD.
CNTB stock price is 1.54 USD.
CNTB stock price (1.54 USD) is 27% less than its Intrinsic Value (2.11 USD).
CNTB. Open Relative Valuation
CNTB has upside potential of 331% compared to the average analyst price target.
Open Wall St Estimates
CNTB has negative Free Cash Flow for the last twelve months.
CNTB has negative Operating Income for the last twelve months.
CNTB has negative Net Income for the last twelve months.
Valuation Backtest
Connect Biopharma Holdings Ltd
Run backtest to discover the historical profit from buying and selling
CNTB
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Connect Biopharma Holdings Ltd
Balance Sheet Decomposition
Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Ltd
Earnings Waterfall
Connect Biopharma Holdings Ltd
|
Revenue
|
0
CNY
|
|
Operating Expenses
|
-784.1m
CNY
|
|
Operating Income
|
-784.1m
CNY
|
|
Other Expenses
|
-12.9m
CNY
|
|
Net Income
|
-797.1m
CNY
|
Free Cash Flow Analysis
Connect Biopharma Holdings Ltd
What is Free Cash Flow?
CNTB Profitability Score
Profitability Due Diligence
Connect Biopharma Holdings Ltd's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
Connect Biopharma Holdings Ltd's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
CNTB Solvency Score
Solvency Due Diligence
Connect Biopharma Holdings Ltd's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Connect Biopharma Holdings Ltd's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CNTB Price Targets Summary
Connect Biopharma Holdings Ltd
According to Wall Street analysts, the average 1-year price target for
CNTB
is 6.63 USD
with a low forecast of 6.06 USD and a high forecast of 7.35 USD.
Shareholder Return
CNTB Price
Connect Biopharma Holdings Ltd
| Average Annual Return | -76.73% |
| Standard Deviation of Annual Returns | 12.37% |
| Max Drawdown | -98% |
| Market Capitalization | 83.4m USD |
| Shares Outstanding | 55 071 600 |
| Percentage of Shares Shorted | 0.37% |
Company Profile
Connect Biopharma Holdings Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 108 full-time employees. The company went IPO on 2021-03-19. Its product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis (AD), and asthma. The company is also developing CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1, (S1P1), for the treatment of inflammatory bowel disease (IBD). The firm mainly conducts its businesses in the China market.
Contact
IPO
Employees
Officers
The intrinsic value of one
CNTB
stock under the Base Case scenario is
2.11
USD.
Compared to the current market price of 1.54 USD,
Connect Biopharma Holdings Ltd
is
Undervalued by 27%.
You don't have any saved screeners yet
